Evidence map›Paper›PMID 41881958›Full record

ArticleCell death & disease2026

Malic enzyme 1 contributes to tumorigenesis and lenvatinib resistance in hepatocellular carcinoma via FSP1-dependent ferroptosis evasion.

Danyi Wu, Huanhuan Xu, Yi Guo, Lulu Lu, Dan Han, Luyi Chen, Ruoxuan Lei, Min Li, Wei Wu, Wen-Zhuo He and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Danyi WuSchool of Public Health and Nursing, Zhejiang Key Laboratory of Medical Epigenetics, Hangzhou Normal University, Hangzhou, China.
Huanhuan XuSchool of Public Health and Nursing, Zhejiang Key Laboratory of Medical Epigenetics, Hangzhou Normal University, Hangzhou, China.
Yi GuoSchool of Public Health and Nursing, Zhejiang Key Laboratory of Medical Epigenetics, Hangzhou Normal University, Hangzhou, China.
Lulu LuSchool of Public Health and Nursing, Zhejiang Key Laboratory of Medical Epigenetics, Hangzhou Normal University, Hangzhou, China.
Dan HanDepartment of Nutrition and Food Safety, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Luyi ChenDepartment of General Practice, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Ruoxuan LeiSchool of Public Health and Nursing, Zhejiang Key Laboratory of Medical Epigenetics, Hangzhou Normal University, Hangzhou, China.
Min LiSchool of Public Health and Nursing, Zhejiang Key Laboratory of Medical Epigenetics, Hangzhou Normal University, Hangzhou, China.
Wei WuSchool of Public Health and Nursing, Zhejiang Key Laboratory of Medical Epigenetics, Hangzhou Normal University, Hangzhou, China.
Wen-Zhuo HeSun Yat-sen University Cancer Center, Guangzhou, China.
Yingying YuSchool of Public Health and Nursing, Zhejiang Key Laboratory of Medical Epigenetics, Hangzhou Normal University, Hangzhou, China.
Xuexian FangSchool of Public Health and Nursing, Zhejiang Key Laboratory of Medical Epigenetics, Hangzhou Normal University, Hangzhou, China. xfang@hznu.edu.cn.ORCID http://orcid.org/0000-0001-5414-9888

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82170644National Natural Science Foundation of China (National Science Foundation of China) 82301745Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation) LQ23H250001Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation) LR23H020001
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the most prevalent hepatic malignancy worldwide, accounting for approximately 90% of all primary liver cancer cases. However, the mechanisms involving in liver tumorigenesis and drug resistance remain unclear, largely restricting the clinical management of HCC. Here, we first evaluated the clinical significance of malic enzyme 1 (ME1) in HCC patients and revealed that ME1 was significantly upregulated in tumor tissues and positively correlated with poor prognosis. Gain- and loss-of-function experiments suggested that ME1 promoted HCC cell viability in vitro. Consistently, hepatocyte-specific Me1 knockout (Me1

Indexed as

CarcinogenesisCarcinoma, HepatocellularDrug Resistance, NeoplasmFerroptosisLiver NeoplasmsMalate DehydrogenasePhenylurea CompoundsQuinolinesAnimalsCell Line, TumorHumansMaleMiceMice, KnockoutlenvatinibMalate DehydrogenasePhenylurea CompoundsQuinolines

Identifiers

PMID41881958
PMCPMC13039963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.